Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- Difficult to Enact Clinical Research Bill in Current Diet Session: LDP Health Panel Chief
March 9, 2016
- PMDA Aims to Complete Reviews for 70% of Priority Products within 9 Months in FY2016
March 9, 2016
- MHLW Sorts Out Schemes for Humanitarian Trials, Patient-Initiated Mixed Care
March 8, 2016
- 77.8% of Generics Converge into Single Price Brand in FY2016 Revision: MHLW
March 7, 2016
- Drug Damage Watchdog Says NOAC Makers Paid Big for People Involved in AF Guidelines
March 7, 2016
- Editor’s Pick: Five Healthcare Policy News Headlines for February
March 4, 2016
- MHLW Panel Sets Official Price of Raw Plasma for Coagulation Factor Products at 11,100 Yen per Liter
March 4, 2016
- 439 APIs/1,057 Long-Listed Products Subject to Z2 Price Cut Rule in FY2016 Revisions
March 4, 2016
- AMED Selects 8 Projects for Pre-Orphan Designation System, 3 from Nobelpharma
March 4, 2016
- 416 APIs Eligible for Price Maintenance Scheme in FY2016 Revision; Astellas Only Japanese in Top 10 Premium Winner List
March 4, 2016
- Sovaldi, Harvoni Face 31.7% Price Cut under “Huge Seller” Re-Pricing: MHLW
March 4, 2016
- MHLW to Revise Label Format, Possibly Scrap “Relative Contraindications” and “Careful Administration” Sections
March 3, 2016
- Show Us Your True Self during Surprise Manufacturing Inspections: PMDA Official
March 3, 2016
- FY2016 NHI Pricing Reform to Bring “1 Victory, 1 Defeat, 1 Draw” for Industry: MHLW Official
March 3, 2016
- MHLW Official Calls for Surprise Checks during Notified Inspections
March 2, 2016
- MHLW OKs 38 New APIs in 2015
March 2, 2016
- MHLW’s Onishi Urges Pref. Officials to Prep for Drug Price Survey toward 2017 Revision
March 2, 2016
- Japan Generic Use Rate at 59.7% in October 2015: MHLW
March 2, 2016
- MHLW to Boost Confirmation Process for Review Panel Members’ Claims on Money Received from Drug Makers
March 1, 2016
- MHLW Approves Add’l Indications for Halaven, Rituxan; Opdivo Now OK’ed for Previously Treated Patients
March 1, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…